Now Playing
CRISPR Epigenetics, Cancer Vaccines & the $12B Immunotherapy Surge
Audio is available on Spreaker — see link below.
CRISPR can now reactivate silenced genes without cutting DNA — and the personalized cancer vaccine market is projected to hit $12.3 billion by 2035. Today's briefing covers epigenetic editing, sickle cell therapy, the TRACeR immunotherapy platform, and what's driving one of medicine's fastest-growing markets.
Audio is available on Spreaker — see link below.
A new version of CRISPR can reactivate silenced genes without touching the DNA sequence itself. That's not a minor refinement.
One early target is Sickle Cell disease. The approach here is to reactivate fetal blood genes in a patient's own bone marrow cells.
On the cancer side, a separate development shifts how immunotherapy targets tumor cells. A protein platform called TRACeR was developed to act as what its creators describe as a master key.
The commercial trajectory around all of this is accelerating fast. The personalized cancer vaccine market sits at around three hundred and two million dollars in twenty twenty-five.
Taken together, these developments point in one direction. Gene therapy is moving away from editing sequences and toward adjusting the chemistry around them.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.